FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382645579> ?p ?o ?g. }

• W4382645579 abstract "Abstract Background Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non–small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC. Methods Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) with an Eastern Cooperative Oncology Group performance status of 0-1, any PD-L1 expression, and no EGFR mutations or ALK translocations, received carboplatin area under the curve (AUC) 6 day 1, nab-paclitaxel 100 mg/m2 days 1, 8, 15, and pembrolizumab 200 mg day 1 q21 days for 4 cycles followed by maintenance pembrolizumab q3w. Co-primary endpoints were progression-free survival (PFS) and overall response rate (ORR). Results Forty-six evaluable patients enrolled, 14 in phase I and 32 in phase II, from June 2015 to July 2018 with a median duration of follow-up of 35.4 months. Median time from enrollment to data lock was 42 months. In the ITT population, the ORR was 35%, median PFS was 5.6 months (95% CI, 4.6-8.2), and median OS was 15.4 months (CI, 12.4-28.1). There were no statistical differences in PFS or OS by PD-L1 status. The 2- and 3-year landmark OS rates were 33% and 24%, respectively. Conclusion Carboplatin, nab-paclitaxel, and pembrolizumab are a safe and effective regimen for patients with both squamous and nonsquamous NSCLC. Although this study did not meet the prespecified endpoints, the median and landmark OS results are consistent with durable benefit of this regimen as seen in phase III trials for first-line treatment of advanced NSCLC." @default.
• W4382645579 created "2023-07-01" @default.
• W4382645579 creator A5012380163 @default.
• W4382645579 creator A5021713453 @default.
• W4382645579 creator A5033948459 @default.
• W4382645579 creator A5051283101 @default.
• W4382645579 creator A5065124595 @default.
• W4382645579 creator A5065305886 @default.
• W4382645579 creator A5073338844 @default.
• W4382645579 creator A5074428655 @default.
• W4382645579 creator A5077814055 @default.
• W4382645579 creator A5081588858 @default.
• W4382645579 date "2023-06-30" @default.
• W4382645579 modified "2023-10-18" @default.
• W4382645579 title "Phase I/II Trial of Carboplatin, <i>Nab</i>-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175" @default.
• W4382645579 cites W1627310644 @default.
• W4382645579 cites W1894066899 @default.
• W4382645579 cites W2034751554 @default.
• W4382645579 cites W2164067249 @default.
• W4382645579 cites W2198093519 @default.
• W4382645579 cites W2527905628 @default.
• W4382645579 cites W2529904548 @default.
• W4382645579 cites W2532961791 @default.
• W4382645579 cites W2625023228 @default.
• W4382645579 cites W2796582438 @default.
• W4382645579 cites W2888599070 @default.
• W4382645579 cites W2892640821 @default.
• W4382645579 cites W2925446385 @default.
• W4382645579 cites W2946386783 @default.
• W4382645579 cites W3017322331 @default.
• W4382645579 cites W3037506839 @default.
• W4382645579 cites W4281750878 @default.
• W4382645579 doi "https://doi.org/10.1093/oncolo/oyad180" @default.
• W4382645579 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37390616" @default.
• W4382645579 hasPublicationYear "2023" @default.
• W4382645579 type Work @default.
• W4382645579 citedByCount "0" @default.
• W4382645579 crossrefType "journal-article" @default.
• W4382645579 hasAuthorship W4382645579A5012380163 @default.
• W4382645579 hasAuthorship W4382645579A5021713453 @default.
• W4382645579 hasAuthorship W4382645579A5033948459 @default.
• W4382645579 hasAuthorship W4382645579A5051283101 @default.
• W4382645579 hasAuthorship W4382645579A5065124595 @default.
• W4382645579 hasAuthorship W4382645579A5065305886 @default.
• W4382645579 hasAuthorship W4382645579A5073338844 @default.
• W4382645579 hasAuthorship W4382645579A5074428655 @default.
• W4382645579 hasAuthorship W4382645579A5077814055 @default.
• W4382645579 hasAuthorship W4382645579A5081588858 @default.
• W4382645579 hasBestOaLocation W43826455791 @default.
• W4382645579 hasConcept C121608353 @default.
• W4382645579 hasConcept C126322002 @default.
• W4382645579 hasConcept C143998085 @default.
• W4382645579 hasConcept C2776256026 @default.
• W4382645579 hasConcept C2776694085 @default.
• W4382645579 hasConcept C2777240266 @default.
• W4382645579 hasConcept C2777701055 @default.
• W4382645579 hasConcept C2778239845 @default.
• W4382645579 hasConcept C2778336483 @default.
• W4382645579 hasConcept C2780057760 @default.
• W4382645579 hasConcept C2781413609 @default.
• W4382645579 hasConcept C2781451048 @default.
• W4382645579 hasConcept C31760486 @default.
• W4382645579 hasConcept C71924100 @default.
• W4382645579 hasConceptScore W4382645579C121608353 @default.
• W4382645579 hasConceptScore W4382645579C126322002 @default.
• W4382645579 hasConceptScore W4382645579C143998085 @default.
• W4382645579 hasConceptScore W4382645579C2776256026 @default.
• W4382645579 hasConceptScore W4382645579C2776694085 @default.
• W4382645579 hasConceptScore W4382645579C2777240266 @default.
• W4382645579 hasConceptScore W4382645579C2777701055 @default.
• W4382645579 hasConceptScore W4382645579C2778239845 @default.
• W4382645579 hasConceptScore W4382645579C2778336483 @default.
• W4382645579 hasConceptScore W4382645579C2780057760 @default.
• W4382645579 hasConceptScore W4382645579C2781413609 @default.
• W4382645579 hasConceptScore W4382645579C2781451048 @default.
• W4382645579 hasConceptScore W4382645579C31760486 @default.
• W4382645579 hasConceptScore W4382645579C71924100 @default.
• W4382645579 hasFunder F4320332932 @default.
• W4382645579 hasLocation W43826455791 @default.
• W4382645579 hasLocation W43826455792 @default.
• W4382645579 hasOpenAccess W4382645579 @default.
• W4382645579 hasPrimaryLocation W43826455791 @default.
• W4382645579 hasRelatedWork W1989051367 @default.
• W4382645579 hasRelatedWork W2013653877 @default.
• W4382645579 hasRelatedWork W2529904548 @default.
• W4382645579 hasRelatedWork W2948776902 @default.
• W4382645579 hasRelatedWork W2981688104 @default.
• W4382645579 hasRelatedWork W2988616663 @default.
• W4382645579 hasRelatedWork W3118834521 @default.
• W4382645579 hasRelatedWork W3127521146 @default.
• W4382645579 hasRelatedWork W3166026934 @default.
• W4382645579 hasRelatedWork W4366778943 @default.
• W4382645579 isParatext "false" @default.
• W4382645579 isRetracted "false" @default.
• W4382645579 workType "article" @default.